Pharmaceutical composition containing aminoadamantane compounds useful for the treatment of agranulomatosis, Wegener's granulomatosis and immune deficiency diseases

摘要

In the present invention, there is disclosed the use of an aminoadamantane compound of the general formula (I), in which Ri1, Ri2, Ri3 and Ri4 are selected independently on each other from -NRi5Ri6, -NRi5Ri6Ri7e+, hydrogen, aryl or heteroaryl with up to 7 ring members, alkyl containing 1 to 20 carbon atoms, alkenyl containing 1 to 20 carbon atoms and alkynyl containing 1 to 20 carbon atoms, wherein the alkyl, alkenyl and alkynyl residues can be branched, unbranched or cyclized and optionally substituted with halogen, aryl or heteroaryl with up to 7 ring members with the proviso that at least one of the residues Ri1, Ri2, Ri3 and Ri4 is represented by -NRi5Ri6 or -NRi5Ri6Ri7e+; and Ri5, Ri6 and Ri7 are selected independently on each other from hydrogen, aryl or heteroaryl with up to 7 ring members, alkyl containing 1 to 20 carbon atoms, alkenyl containing 1 to 20 carbon atoms and alkynyl containing 1 to 20 carbon atoms, wherein the alkyl, alkenyl and alkynyl residues can be branched, unbranched or cyclized and optionally substituted with halogen, aryl or heteroaryl with up to 7 ring members, or Ri5 and Ri6, together with the nitrogen atom, form a heterocyclic group with up to 7 ring members; for the preparation of a medicament useful for the treatment of agranulomatosis, Wegener's granulomatosis and/or immune deficiency diseases particularly AIDS, wherein the medicament increases the activity of neutrophils in a patient possessing already activated neutrophils through a concentration of the aminoadamantane compound of the general formula (I) of from 10e-6 to 10e-5 M in blood plasma.